AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16321740 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Tesla MRI using phased-array coils
Number of subjects: 5
Study 16321740 — intervention group
Group type: COMPARATOR
Intervention: 1.5 Tesla MRI using phased-array coils
Number of subjects: 5
Study 12461195 — intervention group
Group type: EXPERIMENTAL
Intervention: DISH (Depression Interview and Structured Hamilton)
Number of subjects: 57
Study 12461195 — intervention group
Group type: EXPERIMENTAL
Intervention: DISH administered by research nurses
Number of subjects: 57
Study 12461195 — intervention group
Group type: EXPERIMENTAL
Intervention: DISH and BDI correlation
Number of subjects: 57
Study 10091793 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC (5-fluorouracil, doxorubicin, cyclophosphamide)
Number of subjects: 170
Study 10091793 — intervention group
Group type: COMPARATOR
Intervention: NA (vinorelbine and doxorubicin)
Number of subjects: 170
Study 10091793 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 170
Study 10091793 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC and NA
Number of subjects: 170
Study 7762527 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of iodized oil A (490 mg I)
Number of subjects: 0
Study 7762527 — intervention group
Group type: EXPERIMENTAL
Intervention: Split dose of iodized oil A (2 x 245 mg I)
Number of subjects: 0
Study 7762527 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of iodized oil B (675 mg I)
Number of subjects: 0
Study 7762527 — intervention group
Group type: COMPARATOR
Intervention: Divided dose of oil A (2 x 245 mg I)
Number of subjects: 0
Study 7762527 — intervention group
Group type: COMPARATOR
Intervention: Oil A (ethyl esters of iodized fatty acids)
Number of subjects: 0
Study 2065322 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma vaccine plus cyclophosphamide (300 mg/m2 i.v. 3 days prior to each vaccine immunization)
Number of subjects: 45
Study 2065322 — intervention group
Group type: COMPARATOR
Intervention: Melanoma vaccine alone
Number of subjects: 45
Study 2065322 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma vaccine plus cyclophosphamide
Number of subjects: 45
Study 2065322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 6634945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment at 0.5 W/cm2
Number of subjects: 13
Study 6634945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment at 1.0 W/cm2
Number of subjects: 13
Study 6634945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment at 1.5 W/cm2
Number of subjects: 13
Study 6634945 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatment at 0.0 W/cm2
Number of subjects: 13
Study 30054773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh copra meal at 12.5% inclusion
Number of subjects: 280
Study 30054773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh copra meal at 25% inclusion
Number of subjects: 280
Study 30054773 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored copra meal at 12.5% inclusion
Number of subjects: 280
Study 30054773 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored copra meal at 25% inclusion
Number of subjects: 280
Study 30054773 — intervention group
Group type: COMPARATOR
Intervention: Corn-soybean meal diet (control)
Number of subjects: 280
Study 29730344 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study 29730344 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 29730344 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of TAVR to SAVR
Number of subjects: 0
Study 29730344 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic analysis (PA)
Number of subjects: 0
Study 29730344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis with TAVR valve system cost at $17,397
Number of subjects: 0
Study 26479024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling training
Number of subjects: 16
Study 26479024 — intervention group
Group type: COMPARATOR
Intervention: Running training
Number of subjects: 16
Study 24105031 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 180 g/kg DM in feed block (FB)
Number of subjects: 4
Study 24105031 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 180 g/kg DM in FB
Number of subjects: 4
Study 24105031 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 150 g/kg DM in FB
Number of subjects: 4
Study 24105031 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 120 g/kg DM in FB
Number of subjects: 4
Study 24105031 — intervention group
Group type: COMPARATOR
Intervention: U‐cas supplementation at 0 g/kg DM in FB
Number of subjects: 4
Study 22115931 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 848
Study 20796154 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched nutrient (aminoleban EN)
Number of subjects: 49
Study 20796154 — intervention group
Group type: COMPARATOR
Intervention: Standard diet only
Number of subjects: 49
Study 17425543 — intervention group
Group type: EXPERIMENTAL
Intervention: OASIS
Number of subjects: 0
Study 17425543 — intervention group
Group type: COMPARATOR
Intervention: Hyaloskin
Number of subjects: 0
Study 16524150 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 94
Study 16524150 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone membrane oxygenator
Number of subjects: 94
Study 16524150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow fiber oxygenator (HFO)
Number of subjects: 94
Study 16524150 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller pumps
Number of subjects: 94
Study 16524150 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pumps
Number of subjects: 94
Study 16524150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both roller and centrifugal pumps
Number of subjects: 94
Study 16524150 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusionists
Number of subjects: 94
Study 11845362 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed tunable dye laser (PDL) for port-wine stains (PWS)
Number of subjects: 0
Study 11845362 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple pulse laser irradiation for hypertrophic PWS
Number of subjects: 0
Study 11845362 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PDL therapy for capillary haemangiomas
Number of subjects: 0
Study 11845362 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL treatment for mixed haemangiomas
Number of subjects: 0
Study 11845362 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention for life/organ-threatening lesions
Number of subjects: 0
Study 11845362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasers for telangiectatic leg veins (TLV)
Number of subjects: 0
Study 9856895 — intervention group
Group type: EXPERIMENTAL
Intervention: C-KIT+ cells in enteritis
Number of subjects: 25
Study 9856895 — intervention group
Group type: EXPERIMENTAL
Intervention: C-KIT+ cells in NEC
Number of subjects: 25
Study 9856895 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 25
Study 7610782 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS) 90 Hz, 30 min, three times/day
Number of subjects: 31
Study 7610782 — intervention group
Group type: COMPARATOR
Intervention: Flat occlusal splint (24 h/day)
Number of subjects: 31
Study 2171853 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich meal (50 g of bovine serum albumin added)
Number of subjects: 8
Study 2171853 — intervention group
Group type: COMPARATOR
Intervention: Protein-free meal (3800 kJ energy content)
Number of subjects: 8
Study 7274405 — intervention group
Group type: EXPERIMENTAL
Intervention: time-limited therapy of 6 sessions within 8 weeks
Number of subjects: 37
Study 7274405 — intervention group
Group type: EXPERIMENTAL
Intervention: time-limited therapy of 12 sessions within 16 weeks
Number of subjects: 37
Study 7274405 — intervention group
Group type: EXPERIMENTAL
Intervention: time-unlimited therapy
Number of subjects: 37
Study 7274405 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 37
Study 30422243 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks)
Number of subjects: 418
Study 30422243 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks)
Number of subjects: 418
Study 28954982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscle injection of testosterone enanthate
Number of subjects: 0
Study 28954982 — intervention group
Group type: COMPARATOR
Intervention: Non-administration (control)
Number of subjects: 0
Study 25209610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (160 mg/800 mg three times daily) plus rifampicin (600 mg once a day)
Number of subjects: 150
Study 25209610 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg twice a day)
Number of subjects: 150
Study 25209610 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole and rifampicin
Number of subjects: 150
Study 25209610 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 150
Study 24018206 — intervention group
Group type: EXPERIMENTAL
Intervention: WRITE Symptoms intervention
Number of subjects: 65
Study 24018206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 21257057 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA) given subcutaneously every 12h for 10 days
Number of subjects: 8
Study 21257057 — intervention group
Group type: COMPARATOR
Intervention: Control (0.5% of BSA in saline)
Number of subjects: 8
Study 21257057 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA)
Number of subjects: 8
Study 19006643 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical exercise program (6 months)
Number of subjects: 20
Study 19006643 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20
Study 17704418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy regimens (including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel)
Number of subjects: 6642
Study 15221881 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with creatine supplementation (5 g/day)
Number of subjects: 20
Study 15221881 — intervention group
Group type: COMPARATOR
Intervention: Resistance training without creatine supplementation (placebo)
Number of subjects: 20
Study 15221881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (resistance training with and without creatine)
Number of subjects: 20
Study 11848236 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration
Number of subjects: 90
Study 11848236 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lignocaine/prilocaine
Number of subjects: 90
Study 11848236 — intervention group
Group type: COMPARATOR
Intervention: No local treatment (Control)
Number of subjects: 90
Study 9576390 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐TV vaccine (titer 4 x 10(5) plaque‐forming units)
Number of subjects: 2282
Study 9576390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2282
Study 7872912 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise (IKE)
Number of subjects: 19
Study 7872912 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercise (ITE)
Number of subjects: 19
Study 7872912 — intervention group
Group type: COMPARATOR
Intervention: No-exercise (NOE)
Number of subjects: 19
Study 3188824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression using inflatable leg splints
Number of subjects: 46
Study 3188824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no splints)
Number of subjects: 46
Study 31564113 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a nationwide education program
Number of subjects: 3585
Study 31564113 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring for at least 1 dying patient per month
Number of subjects: 3585
Study 31564113 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 3585
Study 31564113 — intervention group
Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 3585
Study 31564113 — intervention group
Group type: COMPARATOR
Intervention: Care staff
Number of subjects: 3585
Study 29570598 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) - 3 sets of 10 repetitions of 8 whole-body exercises, with a 2-minute interval between sets.
Number of subjects: 30
Study 29570598 — intervention group
Group type: COMPARATOR
Intervention: Control - stretching and relaxation exercises.
Number of subjects: 30
Study 27142710 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 10 mg/kg
Number of subjects: 73
Study 27142710 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73
Study 25708973 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid hand soap with 100 ppm MI
Number of subjects: 38
Study 25708973 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid hand soap with 50 ppm MI
Number of subjects: 38
Study 25708973 — intervention group
Group type: COMPARATOR
Intervention: Liquid hand soap without MI (negative control)
Number of subjects: 38
Study 23611893 — intervention group
Group type: COMPARATOR
Intervention: CIND (n=92)
Number of subjects: 309
Study 23611893 — intervention group
Group type: COMPARATOR
Intervention: Dementia (n=59)
Number of subjects: 309
Study 23611893 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (n=158)
Number of subjects: 309
Study 23611893 — intervention group
Group type: COMPARATOR
Intervention: CIND vs. Dementia
Number of subjects: 309
Study 23611893 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 309
Study 21908446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of 250 mg acetylsalicylic acid (ASA) + 200 mg paracetamol + 50 mg caffeine (Thomapyrin)
Number of subjects: 179
Study 21908446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 18178197 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 712
Study 18178197 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 712
Study 16154315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile gloves
Number of subjects: 275
Study 16154315 — intervention group
Group type: COMPARATOR
Intervention: Clean gloves
Number of subjects: 275
Study 15071269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ICD therapy
Number of subjects: 0
Study 11084060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 5‐ to 10‐mg load, 1 to 4 mg/d
Number of subjects: 14
Study 11084060 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC) therapy
Number of subjects: 14
Study 11084060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 14
Study 9200324 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum compression bandage applied within 5 min of injury (mean = 2 min)
Number of subjects: 40
Study 9200324 — intervention group
Group type: COMPARATOR
Intervention: Rest and elevation only, with some cases of non-maximum compression after 10-30 min
Number of subjects: 40
Study 9200324 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain injuries
Number of subjects: 40
Study 9200324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic ultrasound investigation
Number of subjects: 40
Study 1348159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (4 g daily)
Number of subjects: 49
Study 1348159 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine (2 g daily)
Number of subjects: 49
Study 1348159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 49
Study 1348159 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine
Number of subjects: 49
Study 2938872 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha h-ANP with angiotensin II
Number of subjects: 7
Study 2938872 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II with placebo
Number of subjects: 7
Study 31704473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Grape Pomace (DGP)
Number of subjects: 24
Study 31704473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Citrus Pulp (DCP)
Number of subjects: 24
Study 31704473 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 24
Study 30056410 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Group (pressure maintained suboccipital inhibition technique)
Number of subjects: 32
Study 30056410 — intervention group
Group type: COMPARATOR
Intervention: Instrumental Group (self-treatment using an Occipivot cushion)
Number of subjects: 32
Study 27028708 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day bright light exposure + environmental light (bright light exposure group)
Number of subjects: 55
Study 27028708 — intervention group
Group type: COMPARATOR
Intervention: Environmental light alone (no intervention group)
Number of subjects: 55
Study 24778002 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh) + conventional care
Number of subjects: 28
Study 24778002 — intervention group
Group type: COMPARATOR
Intervention: Conventional care only
Number of subjects: 28
Study 22341193 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch & Talk (T&T) - mothers touched, sang, or told stories or rhymes to their child during an invasive procedure
Number of subjects: 65
Study 22341193 — intervention group
Group type: COMPARATOR
Intervention: Control - mothers did not have contact with their child during the invasive procedure
Number of subjects: 65
Study 20190350 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% CHO solution
Number of subjects: 12
Study 20190350 — intervention group
Group type: COMPARATOR
Intervention: 6.8% CHO plus 2.2% protein
Number of subjects: 12
Study 18824675 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF cytomorphology
Number of subjects: 282
Study 18824675 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR of rearranged immunoglobulin heavy‐chain genes in CSF
Number of subjects: 282
Study 18824675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial MRI
Number of subjects: 282
Study 18824675 — intervention group
Group type: EXPERIMENTAL
Intervention: Any method (CSF cytomorphology, PCR, MRI)
Number of subjects: 282
Study 18824675 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF pleocytosis (>5/microL)
Number of subjects: 282
Study 18824675 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF protein
Number of subjects: 282
Study 15693981 — intervention group
Group type: EXPERIMENTAL
Intervention: Futility stopping in clinical trials
Number of subjects: 0
Study 15693981 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 12443833 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens 0.625 mg/day (ERT)
Number of subjects: 40
Study 12443833 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with 5 mg/day continuous medroxyprogesterone
Number of subjects: 40
Study 12443833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12443833 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT
Number of subjects: 40
Study 12443833 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 40
Study 12443833 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT and HRT
Number of subjects: 40
Study 10885835 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis C
Number of subjects: 46
Study 10885835 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B
Number of subjects: 46
Study 10885835 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic liver cirrhosis
Number of subjects: 46
Study 8562470 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release verapamil 240 mg once daily
Number of subjects: 1464
Study 8562470 — intervention group
Group type: COMPARATOR
Intervention: chlorthalidone 25 mg once daily
Number of subjects: 1464
Study 8562470 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 25 mg daily (for nonresponders)
Number of subjects: 1464
Study 2292349 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg t.i.d. for 8 weeks
Number of subjects: 16
Study 2292349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7455836 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting benzodiazepines
Number of subjects: 0
Study 7455836 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting benzodiazepines
Number of subjects: 0
Study 31039280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (KE)
Number of subjects: 18
Study 28417318 — intervention group
Group type: EXPERIMENTAL
Intervention: Brenzys autoinjector
Number of subjects: 191
Study 25433464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 60
Study 25433464 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 60
Study 22309885 — intervention group
Group type: EXPERIMENTAL
Intervention: BWL + H
Number of subjects: 201
Study 22309885 — intervention group
Group type: COMPARATOR
Intervention: BWL
Number of subjects: 201
Study 23896782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thumb-Index Finger Method (TIFM)
Number of subjects: 60
Study 23896782 — intervention group
Group type: COMPARATOR
Intervention: Two Finger Method (TFM)
Number of subjects: 60
Study 23896782 — intervention group
Group type: COMPARATOR
Intervention: Two-Thumb Encircling Hands Method (TTEM)
Number of subjects: 60
Study 19821224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia training (supplemental oxygen during training)
Number of subjects: 12
Study 19821224 — intervention group
Group type: COMPARATOR
Intervention: Normoxia training (ambient air during training)
Number of subjects: 12
Study 19821224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia training
Number of subjects: 12
Study 19821224 — intervention group
Group type: COMPARATOR
Intervention: Normoxia training
Number of subjects: 12